BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

ADM Korea to Submit IND for Niclosamide-Based Combination Therapy for Prostate Cancer

IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. Niclosamide-based metab...

July 12, 2024 | News

National Cancer Center and University of Pennsylvania License CCR4 CAR-T Cell Therapy to ARC Therapies Inc.

The National Cancer Center (Tokyo, Japan) and The University of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a ch...

July 12, 2024 | News

A*STAR and SingHealth Collaborate on SGD$18 Million TISHUMAP Project to Transform Drug Discovery in Asia

A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...

July 09, 2024 | News

MGI Australia Partners with University of Queensland to Combat Antimicrobial Resistance

MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science,...

July 09, 2024 | News

Immorna Biotherapeutics to Launch Phase 1/2 Study of Novel mRNA Therapeutic for Cancer

Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics a...

July 09, 2024 | News

Sirnaomics Announces Positive Interim Results for Phase I Clinical Study of RNAi Therapeutic STP122G Targeting Factor XI

Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engagin...

July 09, 2024 | News

Genexine Merges with EPD Bio to Advance Targeted Protein Degradation Technology

Merger with EPD Bio, a biotech developing a target protein degrader (TPD) platform technology Jaehyun Choi, Ph.D. founder and CEO of EPD Bio, join...

July 08, 2024 | News

XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...

July 08, 2024 | News

Aptamer Group and AstraZeneca Collaborate to Advance Targeted siRNA Delivery for Fibrotic Liver Cells

Aptamer Group , the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreem...

July 05, 2024 | News

South Korea's Genexine Merges with EPD Biotherapeutics to Enhance PROTAC Technology and Drug Pipeline

Genexine a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...

July 05, 2024 | News

Eisai Reclaims Full Rights to Farletuzumab Ecteribulin After Ending Collaboration with Bristol Myers Squibb

Eisai Co., Ltd. announced that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and c...

July 04, 2024 | News

Menarini Silicon Biosystems' Fetal Cell-Based NIPT Shows High Accuracy in Genomic Profiling at 2024 FMF World Congress

Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the potential for an automated syst...

July 02, 2024 | News

Thermo Fisher Scientific Introduces Biobased Films for Bioprocessing Containers to Enhance Sustainability in Biologics Manufacturing

Thermo Fisher Scientific Inc., the world leader in serving science, is contributing to the sustainability of biologics therapy manufacturing by leveraging ...

July 01, 2024 | News

Sirnaomics Completes Phase I Clinical Study of STP707 for Pancreatic Cancer with Strong Safety Profile and Promising Disease Stability

Sirnaomics , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group h...

July 01, 2024 | News

Stay Connected